EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
Trending
-
M&A outlook: stronger US deal market in 2026 despite mixed economic signals
28 Oct 2025 Growth -
US Healthcare Cyber Resilience Survey: Why elevating cybersecurity to a strategic priority can drive transformation
03 Nov 2025 -
Beyond cost cutting: AI as the ultimate growth engine
03 Nov 2025 Consulting
As GLP‑1 (glucagon‑like peptide‑1) therapies rapidly gain traction, the impact is rippling through the consumer packaged goods (CPG) and retail industries, specifically in food and beverage. This webcast will explore how these groundbreaking weight‑management and metabolic treatments are reshaping consumption patterns, retail strategies and product innovation within the consumer sector.
Our panelists will discuss:
- How GLP-1 drugs influence appetite and lifestyle choices
- Which CPG, grocery and restaurant categories are seeing sales volume erosion because of changing consumption habits and which are emerging as growth areas
- How CPG brands and retailers can adapt to capture new opportunities while managing risks
Panelists
- Don K. Johnson – Principal, Strategy and Transaction, EY-Parthenon, Ernst & Young LLP | EY - US
- Ranu Carroll, EY-Parthenon Americas Life Sciences Sector Leader
- Liam Li – Senior Director, Strategy and Transaction, EY-Parthenon, Ernst & Young LLP